- Capability group
- Biotechnology & Health Technologies
- Domain
- Critical Technology · Hard Power
- Identifier
- factbase.org/cap/JH8DZ65Q2E
- Reference
- Nuclear medicine Wikipedia
Papers
33.4k
2020–2024
Paper growth
+6%
2020–24 on 2015–19
Patent families
14.5k
2020–2024
Filed abroad
45%
families in more than one office
In the framework
What the capability covers and what it leaves to others, and the indicators it will be measured by.
Bounds
Covers radioisotope and radiation-medicine technology; research reactors and processing facilities belong to Strategic Infrastructure, clinical delivery to Human Capital's health system, and supply concentration is the control-layer read that justifies the node.
Lineage
Carried from v0.0 (formerly Nuclear medicine and radiation therapy) with the same identifier; retained as a standalone capability on supply-chain logic, a global dependence on few producers, rather than on research-field logic.
Indicators
- medical isotope production sharePending
- research reactors producing isotopesPending
- radiopharmaceutical approvalsPending
Research
Papers classified to the capability, by year and by the nation of their authors' institutions, 2020–2024. Read from the v0.0 research topic Nuclear medicine and radiation therapy.
Papers by year
The five leading nations, papers by year
Share of papers, 2020–2024
Of papers with a known author nation; 32% have none and are left out.
- 1United States20.5%6,154 papers
- 2Germany7.5%2,234 papers
- 3China7.4%2,202 papers
- 4Italy4.9%1,468 papers
- 5United Kingdom4.7%1,403 papers
- 6Japan4.4%1,333 papers
- 7Canada3.9%1,171 papers
- 8France3.3%980 papers
- 9Netherlands3.2%967 papers
- 10India3.2%952 papers
Leading institutions, 2020–2024
By fractional count: each paper divided among its authors' institutions.
- 1Memorial Sloan Kettering Cancer Center196fractional papers
- 2The University of Texas MD Anderson Cancer Center169fractional papers
- 3University of California, Los Angeles130fractional papers
- 4University of California, San Francisco91fractional papers
- 5Johns Hopkins University90fractional papers
- 6Chinese Academy of Medical Sciences & Peking Union Medical College88fractional papers
- 7Stanford University87fractional papers
- 8Cornell University83fractional papers
- 9Washington University in St. Louis78fractional papers
- 10Peking University67fractional papers
Patents
Patent families by the nation of origin of their applicants and their earliest priority year, from the CPC and IPC classes the capability is read from. 2025 onwards is incomplete: families are published 18 months after priority.
Families by priority year
The five leading origins, families by year
10,674 applicants filed here in 2015–2024; the five largest held 5% of families (HHI 13 of 10,000: unconcentrated).
Share of families by origin, 2020–2024
- 1China51.4%7,448 families
- 2United States18.1%2,625 families
- 3Japan7.6%1,097 families
- 4South Korea6.1%878 families
- 5Germany3.1%447 families
- 6Switzerland2.4%345 families
- 7United Kingdom1.5%216 families
- 8Canada1.5%211 families
- 9France1.1%155 families
- 10Netherlands0.9%134 families
Applicants filing most internationally, 2015–2024
Families filed in more than one office, by applicant as the offices name them.
- 1KONINKLIJKE PHILIPS NV318international families
- 2SHANGHAI UNITED IMAGING HEALTHCARE CO LTD297international families
- 3SIEMENS HEALTHINEERS INT AG213international families
- 4SIEMENS HEALTHCARE GMBH186international families
- 5HITACHI LTD184international families
- 6Elekta ltd174international families
- 7CANON MEDICAL SYSTEMS CORP162international families
- 8UNIV CALIFORNIA152international families
- 9OUR UNITED CORP150international families
- 10VARIAN MED SYS INC128international families
Classification read
- A61K51/00 Radiopharmaceuticals · 167.5k documents
- G21G Radioisotope production and radioactive sources · 27.4k documents
- H05H6/00 Targets for producing isotopes by nuclear reaction · 3.9k documents
- H05H13/00 Cyclotrons · 5.9k documents
- C07B59/00 Isotope-labelled organic compounds · 36.1k documents
- A61N5/10 Radiotherapy: X-ray, gamma, particle beams, brachytherapy · 253.4k documents
- G01T1/161 Radiation detection for nuclear medicine · 20.4k documents
- A61B6/037 Emission tomography (PET, SPECT) · 24.1k documents
Shares inventions with
Capabilities whose classes the same families also fall in, by overlap (Jaccard).
- Advanced Therapeutics, Vaccines & Medical Countermeasures1,911 families · 0.022
- Advanced Nuclear & Fusion255 families · 0.015
Companies
50 companies in this capability, across 8 regions. The leading 12:
- 1Siemens HealthineersLeading maker of SPECT and PET/CT scanners (Biograph line) and, through PETNET Solutions, one of the largest PET radiopharmaceutical manufacturing and distribution networks; also owns Varian radiotherapy.Manufacture
- 2GE HealthCareMajor supplier of PET/CT, SPECT/CT and cyclotrons plus a Pharmaceutical Diagnostics unit making SPECT and PET tracers (e.g. DaTscan, Vizamyl) and owner of the MIM Software molecular-imaging suite.Manufacture
- 3NovartisGlobal leader in radioligand therapy with Lutathera and Pluvicto (Lu-177), produced by its Advanced Accelerator Applications unit across dedicated radiopharmaceutical plants.Design
- 4CuriumOne of the world's largest nuclear medicine companies, a top supplier of Mo-99/Tc-99m generators, I-131 and SPECT/PET radiopharmaceuticals, formed from Mallinckrodt Nuclear Medicine and IBA Molecular.Manufacture
- 5Lantheus HoldingsMarkets the leading PSMA PET agent Pylarify, TechneLite Tc-99m generators and cardiac imaging agents, and is building a radiotherapeutics pipeline.Manufacture
- 6Cardinal HealthOperates the largest US network of nuclear pharmacies and cyclotron PET facilities through its Nuclear and Precision Health Solutions business, dispensing unit-dose radiopharmaceuticals.Operation
- 7RosatomRussian state nuclear corporation whose subsidiaries (JSC Isotope, Rusatom Healthcare, research reactors) are major exporters of Mo-99, Lu-177, Co-60, I-131 and other medical isotopes.Manufacture
- 8NRG|PALLASOperates the High Flux Reactor at Petten, historically a supplier of a large share of the world's Mo-99 and Lu-177 targets, and is building the PALLAS replacement isotope reactor.Operation
- 9Institute for Radioelements (IRE)One of the few global processors of irradiated uranium targets into Mo-99, supplying a significant share of world demand, and a producer of therapeutic isotopes.Manufacture
- 10NTP RadioisotopesSubsidiary of South Africa's Necsa that processes Mo-99 from the SAFARI-1 reactor and is one of the world's major Mo-99 and I-131 suppliers, exporting to over 60 countries.Manufacture
- 11ANSTOAustralia's nuclear agency, operating the OPAL reactor and ANSTO Nuclear Medicine Mo-99 plant that supply Tc-99m generators domestically and for export.Manufacture
- 12BWX TechnologiesIts BWXT Medical unit (Ottawa, acquired from Nordion) produces I-125, Y-90 and other isotopes and has developed a non-HEU Mo-99/Tc-99m generator.Manufacture
